RT Journal Article
SR Electronic
T1 Age differential analysis of COVID-19 second wave in Europe reveals highest incidence among young adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20230177
DO 10.1101/2020.11.11.20230177
A1 Alberto Aleta
A1 Yamir Moreno
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.11.20230177.abstract
AB Most of the western nations have been unable to suppress the COVID-19 and are currently experiencing second or third surges of the pandemic. Here, we analyze data of incidence by age groups in 25 European countries, revealing that the highest incidence of the current second wave is observed for the group comprising young adults (aged 18-29 years old) in all but 3 of the countries analyzed. We discuss the public health implications of our findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAA and YM acknowledge partial support from Intesa Sanpaolo Innovation Center. YM acknowledges partial support from the Government of Aragon and FEDER funds, Spain through grant E36-20R (FENOL) and 17030/5423/440189/91019, and by MINECO and FEDER funds (FIS2017-87519-P). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Does not applyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this work is available from the authors.